Want to join the conversation?
In Sept., $REGN and BARDA of the U.S. HHS agreed to develop, test, and manufacture a monoclonal antibody therapy for treatment of Ebola virus infection. HHS will provide initial funding of about $17MM to support preclinical development and antibody manufacturing. HHS also has option to provide for up to additional $32.2MM for Phase 1 study.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.